【摘 要】
：
Current and traditional technologies and products can not cure late-stage and terminal cancer patients are due to 1) side-effects in damaging normal cell,ti
【机 构】
：
BioMedicureUSA&China
论文部分内容阅读
Current and traditional technologies and products can not cure late-stage and terminal cancer patients are due to 1) side-effects in damaging normal cell,tissue,organ or system,2) limited effects in eliminating or killing some populations of cancer cells that are mutating,infiltrating,and metastasizing over time and 3) 0 effect in making a patients immune system to memorize any cancer cell population being removed or killed.
其他文献
The oncolytic virus was recently become a very hot topic and OncoHSV-GM-CSF has been licensed to be marketed by FDA.We innovate the Cancer Targeting Gene-Vi
Precision (or personalized) cancer therapy matches patients with therapies based upon specific biomarkers (mutations leading to neo-antigens;cell surface an
Glypican-5 (GPC5) is a member of the heparin sulfate proteoglycans.In present study,we confirmed that GPC5 was downregulated in lung adenocarcinoma tissues